DrugCite
Search

MULTIHANCE

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Multihance Adverse Events Reported to the FDA Over Time

How are Multihance adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Multihance, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Multihance is flagged as the suspect drug causing the adverse event.

Most Common Multihance Adverse Events Reported to the FDA

What are the most common Multihance adverse events reported to the FDA?

Nephrogenic Systemic Fibrosis
1694 (7.07%)
Pain
1378 (5.75%)
Anxiety
803 (3.35%)
Emotional Distress
764 (3.19%)
General Physical Health Deteriorati...
719 (3%)
Fibrosis
649 (2.71%)
Mobility Decreased
648 (2.71%)
Scar
601 (2.51%)
Injury
566 (2.36%)
Skin Induration
521 (2.18%)
Skin Hypertrophy
501 (2.09%)
Show More Show More
Skin Tightness
495 (2.07%)
Oedema Peripheral
463 (1.93%)
Joint Range Of Motion Decreased
435 (1.82%)
Skin Fibrosis
426 (1.78%)
Nausea
373 (1.56%)
Deformity
369 (1.54%)
Pruritus
324 (1.35%)
Pain In Extremity
314 (1.31%)
Anhedonia
313 (1.31%)
Vomiting
308 (1.29%)
Hypersensitivity
301 (1.26%)
Musculoskeletal Stiffness
290 (1.21%)
Erythema
286 (1.19%)
Skin Discolouration
277 (1.16%)
Joint Contracture
273 (1.14%)
Joint Stiffness
272 (1.14%)
Muscular Weakness
238 (.99%)
Arthralgia
219 (.91%)
Dyspnoea
211 (.88%)
Skin Hyperpigmentation
197 (.82%)
Gait Disturbance
189 (.79%)
Urticaria
171 (.71%)
Skin Exfoliation
170 (.71%)
Dry Skin
165 (.69%)
Hypoaesthesia
164 (.68%)
Skin Disorder
159 (.66%)
Extremity Contracture
154 (.64%)
Asthenia
143 (.6%)
Skin Plaque
142 (.59%)
Pain Of Skin
133 (.56%)
Rash
133 (.56%)
Oedema
125 (.52%)
Burning Sensation
123 (.51%)
Paraesthesia
110 (.46%)
Skin Lesion
108 (.45%)
Muscle Tightness
107 (.45%)
Anaphylactoid Reaction
101 (.42%)
Loss Of Consciousness
99 (.41%)
Fatigue
98 (.41%)
Anaphylactic Reaction
97 (.4%)
Cardiac Arrest
97 (.4%)
Muscle Contracture
93 (.39%)
Depression
86 (.36%)
Bone Pain
84 (.35%)
Myalgia
83 (.35%)
Joint Swelling
78 (.33%)
Motor Dysfunction
78 (.33%)
Skin Ulcer
77 (.32%)
Abasia
76 (.32%)
Back Pain
75 (.31%)
Rash Macular
74 (.31%)
Pruritus Generalised
70 (.29%)
Rash Papular
65 (.27%)
Anaphylactic Shock
64 (.27%)
Swelling
61 (.25%)
Skin Burning Sensation
59 (.25%)
Discomfort
56 (.23%)
Sneezing
56 (.23%)
Skin Swelling
55 (.23%)
Chest Pain
54 (.23%)
Quality Of Life Decreased
54 (.23%)
Hypotension
51 (.21%)
Dysstasia
50 (.21%)
Hyperhidrosis
47 (.2%)
Myosclerosis
45 (.19%)
Skin Fissures
44 (.18%)
Cardio-respiratory Arrest
43 (.18%)
Convulsion
43 (.18%)
Dizziness
43 (.18%)
Exfoliative Rash
43 (.18%)
Cough
42 (.18%)
Feeling Hot
42 (.18%)
Malaise
41 (.17%)
Respiratory Arrest
36 (.15%)
Skin Atrophy
34 (.14%)
Tremor
33 (.14%)
Chest Discomfort
32 (.13%)
Headache
32 (.13%)
Depressed Level Of Consciousness
31 (.13%)
Retching
31 (.13%)
Throat Tightness
31 (.13%)
Contrast Media Reaction
30 (.13%)
Hyperkeratosis
30 (.13%)
Ocular Icterus
29 (.12%)
Pulse Absent
29 (.12%)
Throat Irritation
29 (.12%)
Feeling Abnormal
28 (.12%)
Renal Failure
28 (.12%)
Renal Failure Acute
27 (.11%)
Pigmentation Disorder
26 (.11%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Multihance, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Multihance is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Multihance

What are the most common Multihance adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Multihance, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Multihance is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Multihance According to Those Reporting Adverse Events

Why are people taking Multihance, according to those reporting adverse events to the FDA?

Nuclear Magnetic Resonance Imaging
2008
Nuclear Magnetic Resonance Imaging ...
461
Angiogram
223
Drug Use For Unknown Indication
138
Imaging Procedure
130
Product Used For Unknown Indication
92
Show More Show More
Headache
64
Diagnostic Procedure
64
Nuclear Magnetic Resonance Imaging ...
63
Back Pain
44
Multiple Sclerosis
26
Convulsion
23
Mass
21
Scan With Contrast
20
Cerebrovascular Accident
19
Dizziness
17
Hypoaesthesia
17
Pain
15
Deafness
13
Scan
13
Fistulogram
13
Venogram
13
Breast Cancer
11
Arteriogram Renal
11
Arteriogram Carotid
11
Tinnitus
11
Metastasis
11
Peripheral Vascular Disorder
10
Hypertension
10
Meningioma
10
Transient Ischaemic Attack
10
Pituitary Tumour Benign
9
Computerised Tomogram
9
Syncope
9
Muscular Weakness
9
Liver Scan
8
Brain Neoplasm
8
Intermittent Claudication
8
Osteomyelitis
8
Pain In Extremity
8
Asthenia
7
Multiple Myeloma
7
Neoplasm
7
Hepatic Neoplasm Malignant
7
Paraesthesia
7
Vertigo
7
Migraine
7
Arteriogram
6
Angiogram Peripheral
6
Hypothalamo-pituitary Disorder
6
Neoplasm Malignant
6

Drug Labels

LabelLabelerEffective
MultihanceBracco Diagnostics Inc11-JUL-12
MultihanceBracco Diagnostics Inc11-JUL-12

Multihance Case Reports

What Multihance safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Multihance. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Multihance.